These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9229361)

  • 1. The effect of OM-89 (Subreum) on the murine model of systemic lupus erythematosus MRL-lpr/lpr.
    Dhaher YY; Khamashta MA; Hartley B; Taub N; Farine JC; Hughes GR
    Lupus; 1997; 6(5):436-40. PubMed ID: 9229361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
    Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
    Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral administration of malathion on the course of disease in MRL-lpr mice.
    Rodgers KE
    J Autoimmun; 1997 Aug; 10(4):367-73. PubMed ID: 9237800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice].
    Ding ZX; Yang SF; Wu QF; Lu Y; Chen YY; Nie XL; Jie HY; Qi JM; Wang FS
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Apr; 31(4):656-60. PubMed ID: 21515463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
    Anders HJ; Vielhauer V; Eis V; Linde Y; Kretzler M; Perez de Lema G; Strutz F; Bauer S; Rutz M; Wagner H; Gröne HJ; Schlöndorff D
    FASEB J; 2004 Mar; 18(3):534-6. PubMed ID: 14734643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
    Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a pure compound H1-A extracted from Cordyceps sinensis on autoimmune disease of MRL lpr/lpr mice.
    Yang LY; Chen A; Kuo YC; Lin CY
    J Lab Clin Med; 1999 Nov; 134(5):492-500. PubMed ID: 10560943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL; Tsang R; Wong D; Chan KW; Chan TM; Fung PC; Lai KN
    Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis.
    Albrightson-Winslow CR; Brickson B; King A; Olivera D; Short B; Saunders C; Badger AM
    J Pharmacol Exp Ther; 1990 Oct; 255(1):382-7. PubMed ID: 2145424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.
    Zhang MC; Misu N; Furukawa H; Watanabe Y; Terada M; Komori H; Miyazaki T; Nose M; Ono M
    Ann Rheum Dis; 2006 Apr; 65(4):495-500. PubMed ID: 16150787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
    Entani C; Izumino K; Iida H; Fujita M; Asaka M; Takata M; Sasayama S
    Nephron; 1993; 64(3):471-5. PubMed ID: 7688103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG anti-cardiolipin antibodies in murine lupus.
    Gharavi AE; Mellors RC; Elkon KB
    Clin Exp Immunol; 1989 Nov; 78(2):233-8. PubMed ID: 12412755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
    Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
    Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of BET protein BRD4 delays murine lupus.
    Wei S; Sun Y; Sha H
    Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.
    Ikeda T; Fujii H; Nose M; Kamogawa Y; Shirai T; Shirota Y; Ishii T; Harigae H
    Arthritis Res Ther; 2017 Aug; 19(1):187. PubMed ID: 28800777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.